Karin Berghoff

560 total citations
28 papers, 277 citations indexed

About

Karin Berghoff is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Karin Berghoff has authored 28 papers receiving a total of 277 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Karin Berghoff's work include Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Karin Berghoff is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Karin Berghoff collaborates with scholars based in Germany, United States and France. Karin Berghoff's co-authors include Morten Mau‐Sørensen, Lars Damstrup, Henk M.W. Verheul, Jan H.M. Schellens, Dorte Nielsen, Patrick Schöffski, Mirjam Kuipers, Maja J.A. de Jonge, Samer El Bawab and Mark T. J. van Bussel and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Karin Berghoff

28 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karin Berghoff Germany	8	134	123	120	69	43	28	277
Philippe Jamme France	9	110 0.8×	149 1.2×	106 0.9×	84 1.2×	44 1.0×	22	256
Eisuke Kurihara Japan	8	148 1.1×	113 0.9×	110 0.9×	38 0.6×	32 0.7×	12	271
Simon Baldacci France	10	145 1.1×	244 2.0×	139 1.2×	107 1.6×	59 1.4×	24	364
Chen‐Yang Huang Taiwan	11	180 1.3×	139 1.1×	65 0.5×	19 0.3×	58 1.3×	37	356
Sabine Glaser Switzerland	5	137 1.0×	211 1.7×	104 0.9×	50 0.7×	38 0.9×	8	296
Jayne Gurtler United States	7	188 1.4×	98 0.8×	68 0.6×	120 1.7×	82 1.9×	14	332
Cristina Aguayo Spain	7	167 1.2×	85 0.7×	85 0.7×	42 0.6×	99 2.3×	17	301
Gennaro Palmiotti Italy	9	163 1.2×	105 0.9×	74 0.6×	42 0.6×	33 0.8×	22	332
Samson Ghebremariam United States	7	99 0.7×	217 1.8×	65 0.5×	52 0.8×	27 0.6×	13	262
Hideko Isozaki Japan	9	207 1.5×	198 1.6×	209 1.7×	20 0.3×	43 1.0×	31	374

Countries citing papers authored by Karin Berghoff

Since Specialization

Citations

This map shows the geographic impact of Karin Berghoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Berghoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Berghoff more than expected).

Fields of papers citing papers by Karin Berghoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Berghoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Berghoff. The network helps show where Karin Berghoff may publish in the future.

Co-authorship network of co-authors of Karin Berghoff

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Berghoff. A scholar is included among the top collaborators of Karin Berghoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Berghoff. Karin Berghoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thomas, Michael, Petros Christopoulos, Wade T. Iams, et al.. (2025). MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. Journal of Comparative Effectiveness Research. 14(2). e240127–e240127. 1 indexed citations

Amato, Federico, Rainer Strotmann, Roberto Castello, et al.. (2024). Explainable machine learning prediction of edema adverse events in patients treated with tepotinib. Clinical and Translational Science. 17(9). e70010–e70010. 2 indexed citations

Nadal, Ernest, Valentina Guarneri, Marie Wislez, et al.. (2023). 1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC. Annals of Oncology. 34. S780–S781. 1 indexed citations

Liam, Chong Kin, Te‐Chun Hsia, Jianying Zhou, et al.. (2023). Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR -Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clinical Cancer Research. 29(10). 1879–1886. 22 indexed citations

Paik, Paul K., Marina Chiara Garassino, Xiuning Le, et al.. (2023). Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.. Journal of Clinical Oncology. 41(16_suppl). 9060–9060. 2 indexed citations

Cortot, Alexis B., Xiuning Le, Egbert F. Smit, et al.. (2022). Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review. Clinical Lung Cancer. 23(3). 195–207. 34 indexed citations

Griesinger, Frank, Egbert F. Smit, Rémi Veillon, et al.. (2022). 24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy. Annals of Oncology. 33. S40–S41. 2 indexed citations

Yang, James Chih‐Hsin, M-J. Ahn, Hiroya Sakai, et al.. (2022). 25P Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping. Annals of Oncology. 33. S41–S42. 1 indexed citations

Nyberg, Joakim, Orestis Papasouliotis, Andreas Johne, et al.. (2022). Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations. Cancer Chemotherapy and Pharmacology. 90(1). 53–69. 8 indexed citations

10.

Veillon, Rémi, Hiroshi Sakai, Xiuning Le, et al.. (2022). Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. Clinical Lung Cancer. 23(4). 320–332. 6 indexed citations

11.

Kato, Terufumi, James Chih‐Hsin Yang, Myung‐Ju Ahn, et al.. (2022). Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.. Journal of Clinical Oncology. 40(16_suppl). 9120–9120. 1 indexed citations

12.

Ryoo, Baek‐Yeol, Ann‐Lii Cheng, Zhenggang Ren, et al.. (2021). Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer. 125(2). 200–208. 36 indexed citations

13.

Decaens, Thomas, Carlo Barone, Eric Assénat, et al.. (2021). Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer. 125(3). 465–465. 2 indexed citations

14.

Decaens, Thomas, C. Barone, Eric Assénat, et al.. (2021). Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer. 125(2). 190–199. 28 indexed citations

15.

Morise, Masahiro, Hiroshi Sakai, Rémi Veillon, et al.. (2021). O13-4 Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial. Annals of Oncology. 32. S291–S291. 2 indexed citations

16.

Garassino, Marina Chiara, Enriqueta Felip, Hiroshi Sakai, et al.. (2021). 1254P Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC. Annals of Oncology. 32. S984–S985. 4 indexed citations

17.

Paik, Paul K., Orestis Papasouliotis, Richard Anziano, et al.. (2020). 584P Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumours. Annals of Oncology. 31. S494–S495. 5 indexed citations

18.

Bussel, Mark T. J. van, Ahmad Awada, Maja J.A. de Jonge, et al.. (2020). A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. British Journal of Cancer. 124(4). 728–735. 75 indexed citations

19.

Siena, Salvatore, et al.. (2010). Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy.. Journal of Clinical Oncology. 28(15_suppl). 3561–3561. 1 indexed citations

20.

Schinzel, Helmut, et al.. (2006). Anticoagulation with low‐molecular‐weight heparin (dalteparin) in plasmapheresis therapy: initial experience. Transfusion. 46(4). 624–629. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact